DNA Vaccine Protects Against Toxic Proteins Linked to Alzheimer’s
A new DNA vaccine when delivered to the skin prompts an immune response that produces antibodies to protect against toxic proteins associated with Alzheimer’s disease – without triggering severe brain swelling that earlier antibody treatments caused in some patients. Two studies from the Peter O’Donnell Jr. Brain Institute demonstrate in animals how a vaccine containing DNA of the toxic beta-amyloid protein elicits a different immune response that may be safe for humans. The vaccine, which will likely be tested further by the U.S. Food and Drug Administration (FDA), is on a shortlist of promising antibody treatments that may eventually help settle a high-stakes debate of whether amyloid is a vital target for preventing or curing Alzheimer’s.
Click here to read more.
9th World Congress of Neuroendoscopy
Nov. 21-24, 2019; Orlando, Fla.
Medical and Surgical Interventions in ICH: A Practical Workshop
Nov. 23, 2019; Chicago
2nd International Conference on Brain Stimulation
Nov. 27-28, 2019; Dubai, United Arab Emirates
2019 AANS/CNS Section on Pediatric Neurological Surgery Annual Meeting
Dec. 5-8, 2019; Scottsdale, Ariz.
Dec. 5-8, 2019; Mumbai, India